Literature DB >> 19479904

The psychiatrist confronted with a fibromyalgia patient.

Siegfried Kasper1.   

Abstract

Fibromyalgia is usually treated by rheumatologists but since co-morbid depression and anxiety are frequent, psychiatrists are likely to be confronted with patients suffering from the syndrome. The symptoms associated with fibromyalgia vary from patient to patient but there is one common symptom-they ache all over. In addition to pain, patients report headaches, poor sleep, fatigue, depressed mood and irregular bowel habits, which are also all symptoms of depression. For a formal diagnosis of fibromyalgia, the American College of Rheumatology (ACR) criteria require the patient to have widespread pain for at least 3 months together with tenderness at 11 or more of 18 specific tender points.Treatment of fibromyalgia requires a comprehensive approach involving education, aerobic exercise and cognitive behavioural therapy in addition to pharmacotherapy. The most effective drugs available for the treatment for fibromyalgia, the serotonin noradrenaline reuptake inhibitors, milnacipran and duloxetine and the anti-epileptic, pregabalin, are well known to psychiatrists. Thus the psychiatrist is well placed to initiate treatment in these patients. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479904     DOI: 10.1002/hup.1027

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  2 in total

1.  Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort.

Authors:  Pankti Mehta; Amartya Basu; Sakir Ahmed
Journal:  Rheumatol Int       Date:  2022-04-27       Impact factor: 3.580

2.  Abnormal neuroinflammation in fibromyalgia and CRPS using [11C]-(R)-PK11195 PET.

Authors:  Seongho Seo; Ye-Ha Jung; Dasom Lee; Won Joon Lee; Joon Hwan Jang; Jae-Yeon Lee; Soo-Hee Choi; Jee Youn Moon; Jae Sung Lee; Gi Jeong Cheon; Do-Hyung Kang
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.